Navegando por Palavras-chave "Inibidores de ciclooxigenase"

Agora exibindo 1 - 2 de 2
  • Imagem de Miniatura
    Item
    Acesso aberto (Open Access)
    Chemoprevention by celecoxib in reflux-induced gastric adenocarcinoma in Wistar rats that underwent gastrojejunostomy
    (Sociedade Brasileira para o Desenvolvimento da Pesquisa em Cirurgia, 2009-06-01) Rocha, Frederico Theobaldo Ramos; Lourenço, Laércio Gomes [UNIFESP]; Jucá, Mário Jorge; Costa, Valéria; Leal, Antenor Teixeira; Federal University of Alagoas Department of Surgery; Universidade Federal de São Paulo (UNIFESP); UFAL Department of Surgery; UNCISAL Pathology Department
    PURPOSE: To evaluate chemoprevention by celecoxib in cases of reflux-induced gastric adenocarcinoma, in Wistar rats that underwent gastrojejunostomy. METHODS: Sixty male Wistar rats of average age three months underwent surgery and were distributed into three groups: group 1, exploratory laparotomy; group 2, gastrojejunostomy; and group 3, gastrojejunostomy and daily celecoxib administration. After 53 weeks, the animals were sacrificed. Changes in the mucosa of the gastric body of group 1 and in the gastrojejunal anastomosis of groups 2 and 3, observed in histopathological and immunohistochemical examinations, were compared. All statistical analyses were performed using Epi-Info®, version 3.4.3. RESULTS: Comparison between groups 2 and 3 relative to the presence of adenocarcinoma showed a statistically significant difference (p=0.0023). Analysis of the association between groups 2 and 3 relative to COX-2 expression also showed a statistically significant difference (p=0.0018). CONCLUSION: Celecoxib had an inhibiting effect on gastric carcinogenesis induced by enterogastric reflux in an animal model.
  • Imagem de Miniatura
    Item
    Embargo
    Efeito do inibidor da cox-2 lumiracoxibe, do anti-tnf-α etanercepte e da sua associação, na colite induzida pelo 2,4,6-ácido trinitrobenzeno-sulfônico em ratos
    (Universidade Federal de São Paulo (UNIFESP), 2010-07-28) Paiotti, Ana Paula Ribeiro [UNIFESP]; Franco, Marcello Fabiano de [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)
    Aim: The present study aimed to evaluate the effect of lumiracoxib, a selectivecyclooxygenase- 2 (COX-2) inhibitor, and etanercept (ETC), a tumour necrosis factor alpha (TNF-α) antagonist, and the association of both drugs on the 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced experimental colitis. Material and Methods: Wistar rats (n=47) were randomized into seven groups, as follows: 1) Sham: sham induced-colitis; 2) TNBS: nontreated induced-colitis (50 mg/kg); 3) Lumiracoxib control (6 mg/kg); 4) Lumiracoxib-treated induced-colitis; 5) ETC control (5 mg/kg); 6) ETC-treated induced-colitis; 7) Lumiracoxib-ETC-treated induced-colitis. Results: Rats from Groups 2 and 4 presented statistically significant similar macroscopic and histopathological features as compared with the other Groups. There was no reduction in the levels of mRNA and proteic expression of COX-2 and TNF- in these two Groups. Rats from Groups 6 and 7 presented improvement of macroscopic and histopathological damages in the distal colon. In addition they exhibited decreased levels of mRNA expression of COX-2 and TNF-, and down-regulation at the cellular level of these proteins, as well as prostaglandin E2 (PGE2). Conclusions: In TNBS-induced colitis in rats, treatment with lumiracoxib was not able to reduce morphological damages. On the contrary, treatment with etanercept attenuated the intestinal injury, reduced inflammation in TNBS-induced colitis, producing a protective effect on the potential damage caused by lumiracoxib.